# FDA WARNING_LETTER - ABCO Laboratories, Inc. - September 09, 2011

Source: https://www.keypedia.com/records/warning_letter/abco-laboratories-inc/3808e62e-cc1d-472d-a2dc-968c0ebe0659

> FDA WARNING_LETTER for ABCO Laboratories, Inc. on September 09, 2011. Product: Food. Access full analysis and detailed observations.

---

## Details

- Record Type: WARNING_LETTER
- Company Name: ABCO Laboratories, Inc.
- Inspection Date: 2011-09-09
- Product Type: Food
- Office Name: San Francisco District Office
- Summary: The FDA conducted an inspection of ABCO Laboratories, Inc. from August 26 to September 9, 2011, identifying significant violations.

"IBU-RELIEF 12" was found to be an unapproved new drug under Sections 201(g)(1)(C) and 201(P) of the Act [21 U.S.C. §§ 321(g)(1)(C), 321(P)], violating Sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]. Despite being labeled homeopathic, it contains ibuprofen, which is not a recognized homeopathic ingredient, thus not qualifying for CPG 7132.15 enforcement policies.

"Sexual Virility Max" was also deemed an unapproved new drug under Sections 201(g)(1)(C) and 201(P) [21 U.S.C. §§ 321(g)(1)(C), 321(P)], violating Sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]. Laboratory analysis confirmed undeclared sulfoaildenafil and sulfosildenafil,

## Related Documents

- [483 - 2020-03-10](https://www.keypedia.com/records/483/abco-laboratories-inc/15a69543-d5f2-47d7-9333-9509a2c6e832)

## Related Officers

- [Director ](https://www.keypedia.com/people/barbara-j-cassens/26dd2da1-417d-4913-9432-3d50fb3c2f40)
- [Director of Compliance Branch](https://www.keypedia.com/people/lawton-w-lum/96102f66-f6ae-4db9-9ba2-3bc619ae32e2)
- [Carl Lee](https://www.keypedia.com/people/carl-lee/aa605a86-c37b-49db-86a6-a8b953749c99)

Company: https://www.keypedia.com/companies/abco-laboratories-inc/52a761d4-54be-4be8-a992-bf2c3b4edd8c

Office: https://www.keypedia.com/offices/san-francisco-district-office/6f838e9c-aae1-4665-9c46-a51d43be02df